SG11201808650QA - Methods of treating ocular conditions - Google Patents
Methods of treating ocular conditionsInfo
- Publication number
- SG11201808650QA SG11201808650QA SG11201808650QA SG11201808650QA SG11201808650QA SG 11201808650Q A SG11201808650Q A SG 11201808650QA SG 11201808650Q A SG11201808650Q A SG 11201808650QA SG 11201808650Q A SG11201808650Q A SG 11201808650QA SG 11201808650Q A SG11201808650Q A SG 11201808650QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- day
- rat
- pct
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 241000237502 Ostreidae Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- IMIPDPVHGGHVNH-YWVHRCQQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C3[C@H]21 IMIPDPVHGGHVNH-YWVHRCQQSA-N 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000020636 oyster Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319648P | 2016-04-07 | 2016-04-07 | |
| PCT/US2017/026385 WO2017177024A1 (en) | 2016-04-07 | 2017-04-06 | Methods of treating ocular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808650QA true SG11201808650QA (en) | 2018-10-30 |
Family
ID=58549326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808650QA SG11201808650QA (en) | 2016-04-07 | 2017-04-06 | Methods of treating ocular conditions |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10709707B2 (zh) |
| EP (2) | EP3439661B1 (zh) |
| JP (3) | JP7090551B2 (zh) |
| KR (2) | KR102512777B1 (zh) |
| CN (3) | CN114533737B (zh) |
| AU (1) | AU2017248276B2 (zh) |
| BR (1) | BR112018070497A2 (zh) |
| CA (1) | CA3020170A1 (zh) |
| DK (1) | DK3439661T3 (zh) |
| EA (1) | EA201892265A1 (zh) |
| ES (1) | ES2893126T3 (zh) |
| IL (3) | IL299204A (zh) |
| MX (2) | MX2018012230A (zh) |
| MY (1) | MY199237A (zh) |
| NZ (1) | NZ746468A (zh) |
| PH (1) | PH12018502154A1 (zh) |
| PT (1) | PT3439661T (zh) |
| SG (1) | SG11201808650QA (zh) |
| TW (2) | TW202320785A (zh) |
| WO (1) | WO2017177024A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| EP3848028B1 (en) | 2014-10-20 | 2024-05-29 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| CN114533737B (zh) * | 2016-04-07 | 2024-05-31 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| TW202019424A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
| CN112638364A (zh) | 2018-07-10 | 2021-04-09 | 奥伊斯特普安生物制药公司 | 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合 |
| TW202206078A (zh) | 2020-04-28 | 2022-02-16 | 美商奧伊斯特普安生物製藥公司 | 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染 |
| CN117355307A (zh) * | 2021-05-07 | 2024-01-05 | 奥伊斯特普安生物制药公司 | 载体与烟碱激动剂的协同疗法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| WO2003045394A1 (en) | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| WO2004039366A1 (en) | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US7098331B2 (en) | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| US20060270592A1 (en) | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| BRPI0515932A (pt) | 2004-10-15 | 2008-08-12 | Pfizer Prod Inc | composições e métodos para distribuição intranasal, bucal, sublingual e pulmonar de vareniclina |
| US20090023819A1 (en) | 2005-03-22 | 2009-01-22 | Anders Axelsson | Use of an Artificial Sweetener to Enhance Absorption of Nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| TWI404532B (zh) | 2006-11-02 | 2013-08-11 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| BRPI0808634A2 (pt) | 2007-02-02 | 2014-08-05 | Pfizer Prod Inc | Compostos tricíclicos, composições e métodos. |
| WO2008157365A2 (en) * | 2007-06-15 | 2008-12-24 | Targacept, Inc. | Vinylazacycloalkanes for treating neuropathic pain |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| EP2257549A1 (en) | 2008-03-05 | 2010-12-08 | Targacept Inc. | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| CN102143963A (zh) | 2008-09-05 | 2011-08-03 | 塔加西普特公司 | 二氮杂双环辛烷的酰胺及其应用 |
| CN102216289A (zh) * | 2008-10-14 | 2011-10-12 | 塞扣吉尼克斯公司 | 烟碱乙酰胆碱受体配体及其用途 |
| US9145396B2 (en) * | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| TW201024283A (en) | 2008-12-01 | 2010-07-01 | Targacept Inc | Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine |
| US8604191B2 (en) | 2008-12-01 | 2013-12-10 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3YLVINYL)pyrimidine |
| WO2010147938A2 (en) * | 2009-06-17 | 2010-12-23 | Targacept, Inc. | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| CA3083244C (en) | 2011-10-20 | 2023-01-03 | Novartis Ag | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
| WO2013080196A1 (en) | 2011-11-30 | 2013-06-06 | D.E.S. Diagnostics Ltd. | Dry eye diagnostic |
| EP3848028B1 (en) * | 2014-10-20 | 2024-05-29 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| CN114533737B (zh) | 2016-04-07 | 2024-05-31 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
-
2017
- 2017-04-06 CN CN202210034408.5A patent/CN114533737B/zh active Active
- 2017-04-06 CA CA3020170A patent/CA3020170A1/en active Pending
- 2017-04-06 BR BR112018070497A patent/BR112018070497A2/pt active Search and Examination
- 2017-04-06 EP EP17718304.3A patent/EP3439661B1/en active Active
- 2017-04-06 KR KR1020237000103A patent/KR102512777B1/ko active IP Right Grant
- 2017-04-06 KR KR1020187032218A patent/KR102485299B1/ko active IP Right Grant
- 2017-04-06 PT PT177183043T patent/PT3439661T/pt unknown
- 2017-04-06 MY MYPI2018001700A patent/MY199237A/en unknown
- 2017-04-06 EP EP21189296.3A patent/EP3970724A1/en active Pending
- 2017-04-06 CN CN202210040168.XA patent/CN114432313A/zh active Pending
- 2017-04-06 SG SG11201808650QA patent/SG11201808650QA/en unknown
- 2017-04-06 CN CN201780034734.3A patent/CN109310692B/zh active Active
- 2017-04-06 WO PCT/US2017/026385 patent/WO2017177024A1/en active Application Filing
- 2017-04-06 TW TW112102845A patent/TW202320785A/zh unknown
- 2017-04-06 DK DK17718304.3T patent/DK3439661T3/da active
- 2017-04-06 AU AU2017248276A patent/AU2017248276B2/en active Active
- 2017-04-06 ES ES17718304T patent/ES2893126T3/es active Active
- 2017-04-06 JP JP2018553080A patent/JP7090551B2/ja active Active
- 2017-04-06 IL IL299204A patent/IL299204A/en unknown
- 2017-04-06 US US16/091,830 patent/US10709707B2/en active Active
- 2017-04-06 MX MX2018012230A patent/MX2018012230A/es unknown
- 2017-04-06 NZ NZ746468A patent/NZ746468A/en unknown
- 2017-04-06 TW TW106111559A patent/TWI790997B/zh active
- 2017-04-06 EA EA201892265A patent/EA201892265A1/ru unknown
-
2018
- 2018-10-03 IL IL262102A patent/IL262102B/en unknown
- 2018-10-05 MX MX2021010399A patent/MX2021010399A/es unknown
- 2018-10-05 PH PH12018502154A patent/PH12018502154A1/en unknown
-
2020
- 2020-04-17 US US16/852,225 patent/US20200345734A1/en active Pending
-
2022
- 2022-01-24 IL IL290069A patent/IL290069B2/en unknown
- 2022-06-14 JP JP2022095460A patent/JP2022120125A/ja active Pending
-
2024
- 2024-05-29 JP JP2024086805A patent/JP2024103594A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808650QA (en) | Methods of treating ocular conditions | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201901445TA (en) | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |